Rheumatology guidelines are multiplying, and their reach now extends well beyond print
Clinical practice guidelines have become one of the main tools shaping rheumatology care, particularly in diseases where long-term treatment decisions depend on evidence, expert consensus, and careful risk stratification. In this cross-sectional analysis, investigators examined how global rheumatology guidelines perform both academically and socially, using altmetric and citation data to gauge the attention these documents receive after publication.
The dataset was drawn from two of the field’s most visible journals, Annals of the Rheumatic Diseases and Arthritis & Rheumatology, with a search window spanning 2000 through 2024. In total, 127 guidelines met inclusion criteria. For each document, the team recorded the Altmetric Attention Score, Mendeley bookmarking activity, and citation metrics from Scopus and Dimensions on April 9, 2025. The design is straightforward, but the question behind it is not: how does a guideline travel once it leaves the journal page and enters the daily practice of clinicians, trainees, patients, and policy makers?
Guideline output has climbed steadily across the 24-year span
A significant rise in the volume of published guidelines over time was detected. In practical terms, that growth reflects a field under constant pressure to codify care as new biologic agents, diagnostic frameworks, imaging approaches, and treat-to-target strategies emerge. Rheumatology is not a static specialty; it sits at the intersection of inflammatory biology, chronic disability, and long-horizon safety monitoring. As treatment options expand, the need for formal guidance expands with them.
The upward trajectory also suggests that guideline production has become a central academic activity rather than an occasional consensus exercise. As disease definitions evolve and management pathways become more complex, the clinical community depends on documents that can reconcile trial evidence with bedside variability. A guideline in this setting is not simply a literature review. It functions as a practice architecture for common decisions, including when to start, escalate, switch, or de-escalate therapy, and how to balance symptom control against infection risk, organ toxicity, and patient preference.
In rheumatology, that balance is unusually delicate. Many patients live with chronic disease for decades, and many therapies alter immune function in ways that can improve function while increasing vulnerability to harm. Guidelines therefore carry real weight: they influence prescribing behavior, service organization, quality measurement, and educational curricula. When their number rises, the implications reach beyond publication counts.
Online attention and citation metrics measure different forms of influence
This analysis paired Altmetric Attention Score with Mendeley bookmarking and citation counts from two bibliometric databases. Each metric captures a different layer of influence. Citations reflect uptake in the scholarly record, while altmetric measures capture attention across digital and social channels. Mendeley saves often signal early scholarly interest, especially among researchers, fellows, and trainees who may use a guideline as a reference point for future work.
In a specialty like rheumatology, where guideline adoption can affect both high-volume outpatient care and specialized immunology clinics, these metrics matter because visibility is not synonymous with impact, but it is often a precursor to it. A guideline that is widely discussed may prompt faster dissemination, broader teaching, and more immediate recognition of changing recommendations. A guideline with strong citation performance may instead be shaping the evidence ecosystem more quietly through downstream reviews, meta-analyses, and derivative consensus statements.
One sentence captures the tension well: attention and adoption are not the same thing.
That difference matters at the bedside. A document can trend online without changing prescribing habits, and it can alter practice long before social media or news coverage register its existence. In chronic inflammatory disease, where treatment decisions are often individualized, both forms of reach are relevant. One measures visibility; the other measures scholarly traction. Together they help explain how a guideline enters the clinical bloodstream.
Why guideline visibility matters in chronic inflammatory disease
Rheumatic diseases often demand repeated decisions over time rather than a single therapeutic choice. As a result, guideline influence is cumulative. A recommendation about first-line therapy may shape initial management, but another section on monitoring, comorbidity screening, vaccination, or escalation criteria may influence outcomes months or years later. The cumulative nature of rheumatology care makes dissemination especially important, because delayed uptake can translate into inconsistent treatment pathways across centers and countries.
This is also why bibliometric analysis has value beyond academic accounting. It helps reveal which documents are being noticed, saved, and cited in an environment where new evidence appears continuously. For guideline panels, that information can inform future dissemination strategy. For clinicians, it can identify which recommendations are generating the widest professional conversation. For journals, it clarifies how a practice guideline performs as both a scholarly product and a clinical instrument.
The inclusion of two high-impact rheumatology journals makes the analysis particularly relevant to the field’s core literature. These journals often publish the recommendations that shape international practice, and their guideline content tends to influence rheumatologists, allied health professionals, and researchers across multiple health systems. By focusing on documents from 2000 through 2024, the study captures a long era in which rheumatology moved through biologic expansion, tighter disease activity targets, and more explicit emphasis on shared decision-making.
What this analysis can and cannot answer
Cross-sectional bibliometric work can show patterns of attention and scholarly use, but it cannot determine whether higher online visibility improves patient outcomes, changes adherence, or alters prescribing quality. It also cannot prove causality between publication features and metric performance. The study instead provides a map of influence: where attention accumulates, how scholarly uptake is distributed, and how the guideline corpus has grown over time.
For rheumatology, that map is useful because guideline production now sits at the center of evidence translation. A rising number of recommendations means more opportunities to standardize care, but it also raises the burden of keeping clinicians aligned with the latest evidence. The metric mix used here helps identify whether the field’s practice documents are reaching the audiences they are meant to serve.
The most concrete finding is the simplest one: guideline publication in rheumatology has increased substantially over the years examined. The harder question, left open by any bibliometric snapshot, is how effectively those documents move from journal publication to durable clinical change.